Pherin Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Los Altos CA United States (1991)
Status: Acquired by VistaGen Therapeutics, Inc. (2022)

Organization Overview

First Clinical Trial
2008
NCT01217788
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

Fasedienol (2 trials)

sodium phenylbutyrate (buphenyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 3)

Disease (Phase 3)

Phobia, Social (Phase 3)

Phobic Disorders (Phase 2)

Premenstrual Dysphoric Disorder (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2